Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma.
Falchi L, Hutchings M, Carlo-Stella C, Morschhauser F, Dickinson M, Cartron G, Khan C, Tani M, Martinez-Lopez J, Bartlett NL, Salar A, Brody JD, Leppä S, Berthier A, Kallemeijn M, Relf J, Tchaleu FB, Lundberg L, Bachy E. Falchi L, et al. Among authors: bartlett nl. Haematologica. 2024 Nov 28. doi: 10.3324/haematol.2024.286257. Online ahead of print. Haematologica. 2024. PMID: 39605203 Free article.
[No title available]
[No authors listed] [No authors listed] PMID: 39112403
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
Rezazadeh A, Szabo A, Khurana A, Inwards DJ, Lunning MA, Bartlett NL, Caimi PF, Rodgers TD, Barr PM, Chowdhury SM, Epperla N, Mendries H, Hill BT, Oh TS, Karmali R, Chang JE, Goyal G, Parsons BM, Isaac KM, Portell CA, Monahan K, Siker M, King DM, Fenske TS. Rezazadeh A, et al. Among authors: bartlett nl. Haematologica. 2024 May 1;109(5):1439-1444. doi: 10.3324/haematol.2023.283210. Haematologica. 2024. PMID: 37855051 Free PMC article.
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Epperla N, et al. Among authors: bartlett nl. Blood Adv. 2023 Jun 13;7(11):2287-2296. doi: 10.1182/bloodadvances.2022009225. Blood Adv. 2023. PMID: 36516079 Free PMC article.
Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis.
Epperla N, Zhao Q, Moyo T, Watkins MP, Tavakkoli M, Bello C, Torka P, Reddy N, Thomas C, Annunzio K, Christian B, Barta SK, Shouse G, Olszewski AJ, Bartlett NL. Epperla N, et al. Among authors: bartlett nl. Blood Adv. 2024 Feb 13;8(3):549-552. doi: 10.1182/bloodadvances.2023011698. Blood Adv. 2024. PMID: 38091577 Free PMC article. No abstract available.
A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).
Narkhede M, Bartlett NL, Ibrahimi S, Popplewell L, Seto A, Bates J, Lee Y, Ganti V, Han L, Chen T, Patel MR. Narkhede M, et al. Among authors: bartlett nl. EJHaem. 2023 Apr 7;4(2):370-380. doi: 10.1002/jha2.687. eCollection 2023 May. EJHaem. 2023. PMID: 37206279 Free PMC article.
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study.
Annunzio K, Grover NS, Welkie RL, Torka P, Watkins MP, Anampa-Guzmán A, Tavakkoli M, Oh TS, Reves H, Jones D, Hanel W, Christian B, Ramakrishnan Geethakumari P, Karmali R, Barta SK, Bartlett NL, Olszewski AJ, Epperla N. Annunzio K, et al. Among authors: bartlett nl. Blood Adv. 2023 Nov 28;7(22):6839-6843. doi: 10.1182/bloodadvances.2023011288. Blood Adv. 2023. PMID: 37792806 Free PMC article. No abstract available.
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.
Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM, Bouabdallah K, Forward N, Bijou F, MacDonald D, Portell CA, Ghesquieres H, Nowakowski G, Yasenchak CA, Patterson M, Ho L, Rustia E, Fanale M, Jie F, Kim JA. Bartlett NL, et al. J Clin Oncol. 2025 Jan 7:JCO2402242. doi: 10.1200/JCO-24-02242. Online ahead of print. J Clin Oncol. 2025. PMID: 39772655
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas.
Foley N, Riedell PA, Bartlett NL, Cashen AF, Kahl BS, Fehniger TA, Fischer A, Moreno C, Liu J, Carson KR, Mehta-Shah N. Foley N, et al. Among authors: bartlett nl. Clin Lymphoma Myeloma Leuk. 2024 Dec 4:S2152-2650(24)02436-4. doi: 10.1016/j.clml.2024.11.015. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39725584
Sequencing bispecific antibodies and CAR T cells for FL.
Russler-Germain DA, Bartlett NL. Russler-Germain DA, et al. Among authors: bartlett nl. Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):310-317. doi: 10.1182/hematology.2024000667. Hematology Am Soc Hematol Educ Program. 2024. PMID: 39643999 Free PMC article. Review.
293 results